Targeting the Unmet Needs in Cardiovascular Disease Through PCSK9 Inhibition: Recent Advances and Managed Care Insights

CHAPTER MEETING

Wednesday, July 20, 2022
Cooper's Hawk 4515 28th St SE, Kentwood, MI

Networking Hour: 5:30 PM - 6:30 PM
Presentation: 6:30 PM - 7:30 PM

*PT*CE invites you to a Live **Free** Accredited Presentation

EDUCATIONAL OBJECTIVES

After completion of this activity, pharmacists will be able to:

- Illustrate the challenges in treating patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia to target low-density lipoprotein cholesterol goals.
- Explore the efficacy and safety data, as well as the guideline-recommended use of PCSK9 inhibitors in the management of hypercholesterolemia.
- Identify managed care strategies to integrate evidence-based, cost-effective use of PCSK9-inhibiting therapies.

ACCREDITATION STATEMENT

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-000-22-280-L01-P. The activity is available for CE credit through September 21, 2022.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

REGISTER **HERE**

FACULTY

Khalid M. Kamal, MPharm, PhD
Professor and Chair
Department of Pharmaceutical Systems and Policy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Khalid M. Kamal, MPharm., PhD is a Professor and Chair of the Department of Pharmaceutical Systems and Policy at West Virginia University School of Pharmacy. He completed his Bachelors in Pharmacy and Masters in Pharmacology from Bombay College of Pharmacy, Mumbai, India and received his PhD in Health Outcomes Research (2005) from the Department of Pharmaceutical Systems and Policy, West Virginia University. He has been a Visiting Professor teaching pharmacoeconomics and decision modeling courses in Japan and Saudi Arabia and has been involved in establishing several international exchange programs.

Dr. Kamal's primary research and teaching interests have been pharmacoeconomics, patient- reported outcomes, and improving quality of care using real-world data such as electronic medical records and specialty pharmacy data. His research has focused on issues such as cost-effectiveness of treatments, quality of life, productivity costs, economic burden of diseases, and quality of care issues in chronic and rare conditions. Dr. Kamal serves as the Chair of the Faculty Advisory Council within the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He also serves on ISPOR's Health Science Policy Council, which advises the Society on key scientific research and research policy issues in health economics outcomes research. Dr. Kamal is the guest co-editor for a themed issue on Drug Pricing for the Journal Value in Health.